EMA gives green light to additional mRNA COVID-19 vaccine manufacturing facilities

By Rachel Arthur contact

- Last updated on GMT


Related tags: European medicines agency, Pfizer, Moderna, COVID-19 vaccine

The European Medicines Agency’s human medicines committee (EMA CHMP) has this week approved additional manufacturing capacity for Pfizer/BioNTech and Moderna COVID-19 vaccines.

For Pfizer and BioNTech’s Comirnaty, the CHMP has approved Delpharm’s Saint Rémy sur Avre site in France. The facility will manufacture finished product, and is set to provide around 51 million additional doses this year.

A new manufacturing line at BioNTech’s Marburg manufacturing site has also been approved, increasing active substance manufacturing capacity by around 410 million doses this year.

For Moderna’s Spikevax, the CHMP has approved Catalent’s Bloomington, Indiana, US site: which will perform finished product manufacturing. It has also approved several alternative sites responsible for batch control/testing and packaging of the finished product manufactured by Catalent.

Scale-up of the active substance manufacturing process at two sites in the US (Moderna TX, Inc., Norwood, Massachusetts and Lonza Biologics, Inc., Portsmouth, New Hampshire) were already given the green light on July 30. All together, these approvals will allow the production of 40 million additional doses of Spikevax destined for the EU market in the third quarter of 2021.

Related news

Show more

Related products

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Fill-Finish Biologics

Fill-Finish Biologics

Curia | 16-May-2022 | Technical / White Paper

The clinical value of biologics for the treatment of many disease indications has been accompanied by phenomenal sales. By 2026, the global market for...

Related suppliers

Follow us


View more